View Older Stories View More Recent Stories

Apr 1, 2021 08:45AM SkinMedica® Launches Neck Correct Cream for Neck and Décolleté
Apr 1, 2021 08:31AM AbbVie (ABBV) Announces NEJM Publishes 24-Week Results from Phase 3 Study Evaluating RINVOQ in Psoriatic Arthritis
Apr 1, 2021 08:31AM New England Journal of Medicine Publishes 24-Week Results from Phase 3 Study Evaluating RINVOQ™ (upadacitinib) in Psoriatic Arthritis
Mar 31, 2021 08:00AM AbbVie to Host First-Quarter 2021 Earnings Conference Call
Mar 30, 2021 08:01AM AbbVie (ABBV) Announces U.S. FDA Accepts its NDA for Atogepant for the Preventive Treatment of Migraine
Mar 30, 2021 08:00AM U.S. FDA Accepts AbbVie's New Drug Application for Atogepant for the Preventive Treatment of Migraine
Mar 17, 2021 09:11AM AbbVie (ABBV) Announces Extension of Review for sNDA of Upadacitinib for Treatment of Adults with Active Psoriatic Arthritis
Mar 17, 2021 08:45AM AbbVie Announces Extension of Review for Supplemental New Drug Application of Upadacitinib for the Treatment of Adults with Active Psoriatic Arthritis
Feb 25, 2021 08:59AM AbbVie's (ABBV) Allergan Submits NDA to FDA for AGN-190584 to Treat Presbyopia
Feb 25, 2021 08:00AM Allergan, an AbbVie Company, Submits New Drug Application for Investigational AGN-190584 for the Treatment of Presbyopia
Feb 24, 2021 07:14PM HUMIRA® (adalimumab) Receives FDA Approval to Treat Pediatric Patients Living with Moderately to Severely Active Ulcerative Colitis
Feb 23, 2021 08:30AM New REFRESH® DIGITAL Lubricant Eye Drops Tackle Eye Dryness Due to Everyday Screen Use
Feb 22, 2021 08:46AM AbbVie (ABBV) Says Second Phase 3 Induction Study Confirms Upadacitinib Improved Clinical, Endoscopic and Histologic Outcomes in Ulcerative Colitis Patients
Feb 22, 2021 08:45AM Second Phase 3 Induction Study Confirms Upadacitinib (RINVOQ™) Improved Clinical, Endoscopic and Histologic Outcomes in Ulcerative Colitis Patients
Feb 19, 2021 09:16AM AbbVie (ABBV), Evolus (EOLS), and Medytox Announce Resolution of Intellectual Property Litigation
Feb 19, 2021 09:15AM AbbVie, Evolus, and Medytox Announce Resolution of Intellectual Property Litigation
Feb 19, 2021 08:00AM AbbVie to Present at the Cowen 41st Annual Health Care Conference
Feb 18, 2021 10:58AM AbbVie Declares Quarterly Dividend
Feb 12, 2021 08:00AM AbbVie to Present at the 10th Annual SVB Leerink Global Healthcare Conference
Feb 10, 2021 08:16AM AbbVie (ABBV), Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products
Feb 10, 2021 08:15AM AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products
Feb 10, 2021 08:02AM AbbVie (ABBV) Announces BOTOX Receives FDA Approval for Pediatric Detrusor Overactivity Associated with a Neurologic Condition
Feb 10, 2021 08:00AM BOTOX® (onabotulinumtoxinA) Receives FDA Approval for Pediatric Detrusor Overactivity Associated with a Neurologic Condition
Feb 3, 2021 07:38AM AbbVie Reports Full-Year and Fourth-Quarter 2020 Financial Results
Jan 26, 2021 08:45AM CoolSculpting® by Allergan Aesthetics Expands Body Contouring Portfolio With CoolSculpting® Elite
Jan 25, 2021 11:31AM AbbVie (ABBV) Announces European Commission Approves RINVOQ for Treatment of Psoriatic Arthritis and Ankylosing Spondylitis
Jan 25, 2021 11:30AM European Commission Approves AbbVie's RINVOQ™ (Upadacitinib) for the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis
Jan 15, 2021 09:00AM Allergan Aesthetics and Allergan, an AbbVie Company, to Present 16 Neurotoxin Research Abstracts Across Multiple Therapeutic and Cosmetic Indications at the TOXINS 2021 Virtual Conference
Jan 12, 2021 04:05PM Allergan Aesthetics Enters Into Option to Acquire Cypris Medical
Jan 12, 2021 08:00AM AbbVie to Host Fourth-Quarter and Full-Year 2020 Earnings Conference Call
Jan 12, 2021 06:48AM AbbVie (ABBV) to License First TriNKET Immunotherapy Drug Candidate from Dragonfly
Jan 12, 2021 06:45AM Dragonfly Therapeutics Announces AbbVie Opt-In of TriNKET™ Immunotherapy Drug Candidate
Jan 7, 2021 08:47AM AbbVie (ABBV) Risankizumab Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohn's Disease
Jan 7, 2021 08:45AM Risankizumab (SKYRIZI®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohn's Disease
Jan 6, 2021 08:00AM AbbVie to Present at the 39th Annual J.P. Morgan Healthcare Conference
Jan 5, 2021 08:49AM AbbVie (ABBV) Announces Risankizumab Phase 3 Results Demonstrate Improvements in Disease Activity Across Joint and Skin Symptoms Among Psoriatic Arthritis Patients
Jan 5, 2021 08:48AM Risankizumab (SKYRIZI®) Phase 3 Results Demonstrate Improvements in Disease Activity Across Joint and Skin Symptoms Among Psoriatic Arthritis Patients
Dec 23, 2020 07:31AM AbbVie (ABBV) Announces IMBRUVICA U.S. Prescribing Information Updated to Include Long-Term Data for Waldenstrom's Macroglobulinemia
Dec 23, 2020 07:30AM IMBRUVICA® (ibrutinib) U.S. Prescribing Information Updated to Include Long-Term Data for Waldenström's Macroglobulinemia (WM)
Dec 11, 2020 07:33AM AbbVie (ABBV) Announces CHMP Recommends Approvals of RINVOQ for Treatment of Adults with Active Psoriatic Arthritis and Ankylosing Spondylitis
Dec 11, 2020 07:32AM CHMP Recommends the Approvals of RINVOQ™ (Upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis and Ankylosing Spondylitis
Dec 10, 2020 08:46AM AbbVie (ABBV) Announces RINVOQ Achieved Superiority Versus DUPIXENT For Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adults with Atopic Dermatitis
Dec 10, 2020 08:45AM RINVOQ™ (upadacitinib) Achieved Superiority Versus DUPIXENT® (dupilumab) For Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adults with Atopic Dermatitis
Dec 9, 2020 08:46AM AbbVie (ABBV) Announces Upadacitinib Meets Primary and All Ranked Secondary Endpoints in First Phase 3 Induction Study in Ulcerative Colitis
Dec 9, 2020 08:45AM Upadacitinib (RINVOQ™) Meets Primary and All Ranked Secondary Endpoints in First Phase 3 Induction Study in Ulcerative Colitis
Dec 6, 2020 01:00PM Combined Data from Multiple Phase 3 Studies of IMBRUVICA® (ibrutinib) Show Efficacy and Safety in High-Risk, Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Real-World Data Indicating Low
Dec 5, 2020 12:45PM AbbVie Presents Extended Follow-Up Data for Fixed Duration Treatment VENCLEXTA®/VENCLYXTO® (venetoclax) in Chronic Lymphocytic Leukemia (CLL)
Dec 5, 2020 12:30PM IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Shows High Rates of Disease-Free Survival One Year Post-Treatment in Previously Untreated Patients with Chronic Lymphocyti
Dec 2, 2020 08:09AM AbbVie (ABBV) and Frontier Medicines Establish Global Partnership to Discover and Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets
Dec 2, 2020 08:00AM Frontier Medicines and AbbVie Establish Global Partnership to Discover and Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets
View More Recent Stories View Older Stories